| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
INVO Bioscience (NASDAQ:INVO) reported its Q1 earnings results on Monday, May 16, 2022 at 04:05 PM.
Here's what investors need to know about the announcement.
INVO Bioscience beat estimated earnings by 8.0%, reporting an EPS of $-0.23 versus an estimate of $-0.25.
Revenue was down $521.92 thousand from the same period last year.
Last quarter the company beat on EPS by $0.25 which was followed by a 6.06% drop in the share price the next day.
Here's a look at INVO Bioscience's past performance:
| Quarter | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
|---|---|---|---|---|
| EPS Estimate | -0.22 | -0.20 | -0.19 | -0.17 |
| EPS Actual | 0.03 | -0.24 | -0.17 | -0.25 |
| Revenue Estimate | 210.00K | 330.00K | 410.00K | 590.00K |
| Revenue Actual | 3.05M | 218.87K | 208.47K | 684.52K |
To track all earnings releases for INVO Bioscience visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: INVO
